OptimizeRx (OPRX) Receivables (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Receivables data on file, last reported at $36.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 0.71% year-over-year to $36.7 million; the trailing twelve-month figure through Mar 2026 stood at $36.7 million (down 0.71% YoY), and the FY2025 full-year result was $41.7 million, up 0.58% from the prior year.
• Receivables slipped to $36.7 million in Q1 2026, from $41.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $42.3 million in Q4 2023 to a low of $17.8 million in Q3 2022.
• A 5-year average of $29.3 million and a median of $29.7 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables declined 14.14% in 2022 and surged 64.46% in 2023, its largest moves.
• Tracing OPRX's Receivables over 5 years: stood at $25.7 million in 2022, then surged by 64.46% to $42.3 million in 2023, then declined by 2.07% to $41.5 million in 2024, then advanced by 0.58% to $41.7 million in 2025, then fell by 11.98% to $36.7 million in 2026.
• Business Quant data shows OPRX's Receivables at $36.7 million in Q1 2026, $41.7 million in Q4 2025, and $35.9 million in Q3 2025.